| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 9199-VC-050/CF | |||
| Carrier Free | 9199-VC-200/CF | |||
| Carrier Free | 9199-VC-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 6945-OS-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 10291-TA-050 | |||
| Carrier Free | 10291-TA-100 | |||
| Carrier Free | 10291-TA-250 | |||
| Carrier Free | 10291-TA-500 | |||
| Carrier Free | 10291-TA-01M | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 971-TM-050 | |||
| Carrier Free | 971-TM-200 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 425-R1-050/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 7347-WN-025/CF | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | 420-ME-020/CF | |||
| Carrier Free | 420-ME-100/CF | |||
![Western Blot: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - WB analysis of lysates from HeLa cells that were left untreated (blank) or were treated with 10-20 uM each of Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S. The lysates were analyzed for the expression of LC3-1/LC3-II and SQSTM1/p62 using 2ug/ml each of anti-LC3B (NB100-2220) and anti-SQSTM1/p62 (MAB8028) respectively. Anti-Actin (AF4000) was used as a loading control. TatD11 exhibited superior induction of LC3-II and down-regulation of p62 protein when compared to other treatment and control groups.](http://images.novusbio.com/fullsize/Tat-Beclin-1-L11S-Autophagy-Inducing-Peptide---Inactive-Form-Western-Blot-NBP2-49887-img0001.jpg "<b>Biological Strategies Validation. </b>Western Blot: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - WB analysis of lysates from HeLa cells that were left untreated (blank) or were treated with 10-20 uM each of Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S. The lysates were analyzed for the expression of LC3-1/LC3-II and SQSTM1/p62 using 2ug/ml each of anti-LC3B (NB100-2220) and anti-SQSTM1/p62 (MAB8028) respectively. Anti-Actin (AF4000) was used as a loading control. TatD11 exhibited superior induction of LC3-II and down-regulation of p62 protein when compared to other treatment and control groups.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - HeLa GFP-LC3B cells were treated with Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S for 1.5 hours. Thereafter, the cells were stained using NeuroTrace Red or DAPI and analyzed employing fluorescent microscopy. Note the higher number of autophagosomes/GFP-LC3B+ puncta in the images of Tat-D11 and Tat-L11 treated cells when compared to Tat-Beclin 1 and Tat-L11S treated cells.](http://images.novusbio.com/fullsize/Tat-Beclin-1-L11S-Autophagy-Inducing-Peptide---Inactive-Form-Immunocytochemistry-Immunofluorescence-NBP2-49887-img0002.jpg)
![<b>Biological Strategies Validation. </b>In vivo assay: Tat-Beclin 1 L11S Peptide - Scrambled Control [NBP2-49887] - In vivo dose study in mouse kidneys as control for tat-beclin D11 autophagy inducing peptide. Well tolerated by mice at dose of 1mg/kg for 2 days IP. Soluble in PBS. First two lanes (controls) are treated with 1mg/kg tat-beclin scrambled peptide; remaining lanes are treated with tat-beclin D11 autophagy inducing peptide. Image from verified customer review.](http://images.novusbio.com/fullsize/Tat-Beclin-1-L11S-Peptide---Scrambled-Control-In-vivo-assay-NBP2-49887-img0003.jpg)